{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gele T"],"funding":["Agence Nationale de la Recherche","Agence Nationale de Recherches sur le Sida et les Hépatites Virales"],"pagination":["2282"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9696548"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(11)"],"pubmed_abstract":["The development of animal models undergoing long-term antiretroviral treatment (ART) makes it possible to understand a number of immunological, virological, and pharmacological issues, key factors in the management of HIV infection. We aimed to pharmacologically validate a non-human primate (NHP) model treated in the long term with antiretroviral drugs after infection with the pathogenic SIVmac251 strain. A single-dose pharmacokinetic study of tenofovir disoproxil fumarate, emtricitabine, and dolutegravir was first conducted on 13 non-infected macaques to compare three different routes of administration. Then, 12 simian immunodeficiency virus (SIV)-infected (SIV<sup>+</sup>) macaques were treated with the same regimen for two years. Drug monitoring, virological efficacy, and safety were ev"],"journal":["Pharmaceutics"],"pubmed_title":["Pharmacological Validation of Long-Term Treatment with Antiretroviral Drugs in a Model of SIV-Infected Non-Human Primates."],"pmcid":["PMC9696548"],"funding_grant_id":["ANR-10-EQPX-02-01","SIVART ANRS-IDMIT CO1","ANR-11- INBS-0008"],"pubmed_authors":["Desjardins D","Gele T","Le Grand R","Gouget H","Barrail-Tran A","Lambotte O","Dereuddre-Bosquet N","Furlan V"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacological Validation of Long-Term Treatment with Antiretroviral Drugs in a Model of SIV-Infected Non-Human Primates.","description":"The development of animal models undergoing long-term antiretroviral treatment (ART) makes it possible to understand a number of immunological, virological, and pharmacological issues, key factors in the management of HIV infection. We aimed to pharmacologically validate a non-human primate (NHP) model treated in the long term with antiretroviral drugs after infection with the pathogenic SIVmac251 strain. A single-dose pharmacokinetic study of tenofovir disoproxil fumarate, emtricitabine, and dolutegravir was first conducted on 13 non-infected macaques to compare three different routes of administration. Then, 12 simian immunodeficiency virus (SIV)-infected (SIV<sup>+</sup>) macaques were treated with the same regimen for two years. Drug monitoring, virological efficacy, and safety were ev","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-04T19:51:56.902Z","creation":"2025-04-04T19:51:56.902Z"},"accession":"S-EPMC9696548","cross_references":{"pubmed":["36365101"],"doi":["10.3390/pharmaceutics14112282"]}}